Amundi USD High Yield Corporate Bond ESG UCITS ETF (UHYC)

8K out

https://www.marketwatch.com/investing/stock/iqst/financials/secfilings?docid=19562662

$AVAV PT lowered to $220 from $295 at KeyBanc - keeps Overweight rating

GM FOLKSSSS

What timers! Sell huge amounts of shares AND THEN announce the GREAT MAY DELAY! LUCKY, I guess?

ILLR big pop off 3.05 dip. Monster! the resident maggot getting schooled, when you lose all your money in the market, you become the a crying clown.

The new job may be to replace the Top GRIFTER and pave the way for more exiting GRIFTERS?
yves LOUDEST statement was his ackward DEAD SILENCE on the lack of insider buying.

Calling people “useful idiots” isn’t conviction, it’s noise covering up uncertainty.
If the thesis were truly strong, it wouldn’t need insults or hype to stand on its own.

But please continue with your AI mumbo jumbo.

Like I said, GRIFTER yves may be one more Great May delay away from the door.
Oh, it's not his fault, just his biggest fear. It's the industry's fault.
And that cob, that financial planner level guy, that GRIFTER of his gift, well, it APPEARS to some, that was a way to HIDE insider se

You are seeming the picture much clearer now that you ran the numbers…btw…I like your comparison.Keep up with the good work, but try to stay positive. Elite’s team is working hard for all of us loyal long and strong ELTP investors.
Change it to $2.50…you know it is the right move.

I might bump it up to my original "$2.00 or no deal" name after seeing the valuation of Amneal.

Thanks.

Huya to Exclusively Publish The Legend of Swordman: Reunion in Chinese MainlandJune 26, 2026 5:00 AM
PR Newswire (US) class="legendSpanClass"GUANGZHOU, China, class="legendSpanClass"June 26, 2026 /PRNewswire/ -- HUYA Inc. ("Huya" or the

Still stuck at $1.50 or are you moving it up now to $2.55 or higher because of all the things in the pipeline?

The theater hopefully stops, now that you have no financial position.

Shorts banked, it went their way this round.

Drop outs and dosage were the issue, next trial we need to manage this.

Dr.M miss managed it and lied, or got led to belive they were going

It’s understandable how scams work
when you have supposedly mature adults (investors) who ignore proven facts.
And by admitting to have ignored half the story is one of the dumbest things I’ve ever heard of when it comes to investing.

Hilarious

Soooooo….Maybe is why several congress members have been buying shares of FNMA/FMCC. After all…they always have the ‘inside’ scoop lol

Hi Jeunke, you worked in this industrie. How we have to see this compared Yves his job / tasks? What is Yves going to do? Maybe stuppid question……

The thing that's really easy to understand is Liquidmetal has promised so much and produced absolutely nothing. Everyone there all the way down to the janitor have gotten rich off free shares with no production. The promises have been many and not one has produced a dollar. 
Surgical, kn

Completely agree jeunke22, it appears it is being "noticed" already by closely watching, well seasoned veterans with "at least 20 years experience and Executive MBA degrees"... as we have 21 additional Resume submissions in the just the last 12 hours...;)

Lightwave Logic, Inc.

Mark Zuckerberg directed Meta to create a prediction markets app, NYT reports

June 23 (Reuters) - Meta (META.O), opens new tab CEO Mark Zuckerberg recently dispatched a small team at his company to create a smartphone app ?similar to Polymarket and Kalshi, the New York Times reported

Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAIJune 26, 2026 4:23 AM
PR Newswire (US) New multi-country campaign launches in Geneva alongside the European Academy of Neur

$AABB Many Reasons To Like AABB Here

https://investorshub.advfn.com/uimage/uploads/2026/6/26/cecdbAABB-jpg-1.jpg

Maybe also factor in the repeated cries of “FUDster” and worse directed at posters who did not buy into the TGD (The Good Doctor) narrative, the fumbled readouts, the use of odds ratios, the midstream endpoint changes, the trials being too small and too short, the need for a proper confirmatory tria